ADC Discovery and Development

As ADCs drive the next wave of oncology innovation, developers need a seamless path from discovery to IND. ProBio delivers integrated ADC discovery and development solutions, uniting biological characterization, candidate screening, analytical development, and IND-enabling CMC services to accelerate development timelines and advance promising candidates toward the clinic.

From antibody discovery and conjugation optimization to pharmacology assessment and IND-enabling CMC development, ProBio delivers end-to-end ADC expertise to support every stage of development. Our integrated platform empowers teams to make data-driven decisions, achieve robust candidate characterization, and advance programs efficiently.

With a proven track record spanning over 60 ADC discovery projects and over 100 bioassay studies, we help innovators mitigate risk, overcome development challenges, and move promising ADC candidates closer to clinical success.

ADC Bioassay Service

Rapid and high-throughput screening of potential ADC molecules.

Learn More

Therapeutic Antibody Discovery Services

Screen, optimize, and select high-quality antibody leads for ADC development.

Learn More

IND-Enabling CMC Services

One-stop biologics development and manufacturing in as fast as 4 months from gene synthesis to tox batch.

Learn More

Advancing High-Performance ADC Candidates with Confidence

Building Block
3 – 5 months

ADC Screening 3 – 5 months

ADC Optimization & Validation 5 – 6 months

Naked Antibody CMC 7 – 9 months

Conjugation

In vitro assays

In vivo
evaluation

Antibody
engineering

Conjugation

Pharmacology study

Developability

Stable cell line
development

Process
Development

Non-GMP &
GMP Production

Naked
Antibody
Screening

Payload–linker
Selection

DAR
Homogeneity

Affinity, specificity, cross–reactivity
Cell–based killing
Bystander effect

Humanization
Affinity tuning
Fc engineering

DAR
Homogeneity

Affinity, specificity, cross–reactivity
Cell–based killing
Bystander effect

PK/PD/Tox

Stability
Homogeneity

Advancing ADC Discovery Workflows

Target Evaluation

With 60+
discovery project
experiences in
ADC targets,
including HER2,
EGFR, and TROP2

Naked Antibody Discovery

Diverse antibody discovery platforms and biologic modalities
High-throughput functional and internalization screening (>100 antibodies)
Epitope binning to preserve epitope diversity
Data-driven selection of high-potential ADC leads

Payload–linker
Library

150+ cytotoxins
950+ linkers
190+ ready-to- use payload– linker conjugates

ADC Conjugation

Lysine-based conjugation
Cysteine-based conjugation
Site-specific conjugation (Glycan conjugation)
Purity by SEC-HPLC
DAR by HIC-HPLC

In vitro Bioassay

60+ projects in antibody body
Internalization bioassay and 9 types of
ADC bioassay methods including:

Live-cell imaging-based Internalization;
Toxin-conjugated mAb based cytotoxicity assay;
Bystander effect study

In vivo Pharmacology

One-stop Service including:

Pharmacodynamics, pharmacokinetics and toxicology
200+ tumor cell banks
80+ tumor cell models
Covering 24 tumor indications

Developability

Including Tm, Tagg,
purity, solubility,
high-temperature
stability, and freeze-
thaw stability.

Advance your ADC Project with ProBio

Integrated ADC Platform from Discovery to IND

Advance ADC programs through a unified workflow spanning antibody discovery, payload-linker selection, bioassays, pharmacology studies, and antibody IND-enabling CMC, reducing handoffs and accelerating development timelines.

Extensive ADC Discovery & Evaluation Expertise

Leverage 60+ ADC discovery projects, 100+ bioassay studies, high-throughput internalization screening, and diverse in vitro and in vivo pharmacology capabilities to identify and validate promising ADC candidates.

Flexible payload-linker library and conjugation engineering capabilities

Flexible Payload-Linker & Engineering Capabilities

Access 150+ payloads, 950+ linkers, multiple conjugation strategies, and antibody engineering expertise to optimize efficacy, developability, and clinical readiness.